ArticleJournal of Alzheimer's disease reports
Diagnostic association of ante-mortem biomarkers with cerebral amyloid angiopathy in a cohort with high Alzheimer's disease comorbidity.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cerebral amyloid angiopathy (CAA) frequently co-occurs with Alzheimer's disease (AD), complicating the interpretation of biomarkers. Current diagnostic approaches rely largely on neuroimaging but remain constrained by limited accuracy. Objective: This study aimed to evaluate the diagnostic discrimination and pathological association of neuropathological scoring systems and fluid biomarkers for CAA using pathologically confirmed samples. Methods: We examined 100 participants from the Alzheimer's Disease Neuroimaging Initiative with complete neuropathological assessments. Associations and diagnostic performance of amyloid-β (Aβ)-related measures were evaluated using multivariable regression and receiver operating characteristic analyses. Results: Both Thal phase and the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) score were associated with CAA status. Cerebrospinal fluid (CSF) Aβ Conclusions: Neuropathological scores and fluid biomarkers are associated with the presence and severity of CAA, but this association is confounded by co-existing advanced AD pathology. Despite high discriminative accuracy, the small control sample warrants cautious interpretation of specificity estimates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.